文献速递物质与行为成瘾

靶向口服纳曲酮治疗性少数男性轻中度酒精使用障碍的随机试验

Targeted Oral Naltrexone for Mild to Moderate Alcohol Use Disorder Among Sexual and Gender Minority Men: A Randomized Trial.
PubMed 文献 · Am J Psychiatry · 2022-10-26

该双盲安慰剂对照试验将120名有暴饮行为且患轻中度酒精使用障碍的性少数男性按1:1随机分配至靶向口服纳曲酮50 mg或安慰剂组,均接受每周咨询共12周。意向治疗分析显示纳曲酮显著减少暴饮天数、暴饮周数、月饮酒量及渴求评分,且疗效在治疗后6个月仍持续。

要点

  • 靶向纳曲酮减少暴饮天数(IRR=0.74,95%CI=0.56,0.98;NNT=2)。
  • 纳曲酮降低月饮酒量(IRR=0.69,95%CI=0.52,0.91;NNT=5.7 for 10 drinks)。
  • 治疗后6个月仍持续减少月饮酒量与暴饮天数。

核心结论

  • 靶向纳曲酮显著减少性少数男性轻中度酒精使用障碍者的饮酒结局,且治疗后6个月疗效持续。

研究设计与样本

  • 双盲安慰剂对照试验,120名有暴饮行为且患轻中度酒精使用障碍的性少数男性按1:1随机分配至靶向口服纳曲酮50 mg或安慰剂组,均接受每周咨询共12周。

主要发现

  • 意向治疗分析中纳曲酮显著减少暴饮天数(IRR=0.74,95%CI=0.56,0.98;NNT=2)。
  • 纳曲酮显著减少有暴饮的周数(IRR=0.83,95%CI=0.72,0.96;NNT=7.4)。
  • 纳曲酮显著减少月饮酒量(IRR=0.69,95%CI=0.52,0.91;NNT=5.7 for 10 drinks)。
  • 纳曲酮显著降低酒精渴求评分(系数=-9.25,95%CI=-17.20,-1.31)。
  • 在平均每周至少2.5天服药的依从者中,纳曲酮减少暴饮(IRR=0.84,95%CI=0.71,0.99)、暴饮天数(IRR=0.67,95%CI=0.47,0.96)并降低PEth浓度(系数=-55.47,95%CI=-110.75,-0.20)。

关键数值与推荐

  • 意向治疗分析中暴饮天数IRR=0.74(95%CI=0.56,0.98),NNT=2。
  • 意向治疗分析中有暴饮的周数IRR=0.83(95%CI=0.72,0.96),NNT=7.4。
  • 意向治疗分析中月饮酒量IRR=0.69(95%CI=0.52,0.91),NNT=5.7(针对10杯酒)。
  • 治疗后6个月月饮酒量IRR=0.69(95%CI=0.50,0.97)、暴饮天数IRR=0.67(95%CI=0.47,0.95)、过去一周任何暴饮IRR=0.79(95%CI=0.63,0.99)。

临床怎么用

  • 对于有暴饮行为且患轻中度酒精使用障碍的性少数男性,靶向口服纳曲酮50 mg联合每周咨询可考虑作为减少暴饮的药物治疗选择。
  • 治疗期间需关注服药依从性,平均每周至少2.5天服药与更明显的暴饮减少及PEth浓度下降相关。

局限性

  • 原文摘要未报告局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The authors sought to determine the efficacy of targeted naltrexone in sexual and gender minority men (SGM) who binge drink and have mild to moderate alcohol use disorder. METHODS: In a double-blind placebo-controlled trial, a total of 120 SGM who binge drink and have mild to moderate alcohol use disorder were randomized in a 1:1 ratio to receive targeted oral naltrexone (50 mg) or placebo with weekly counseling for 12 weeks. The study's primary endpoints were binge-drinking intensity, defined as 1) number of drinks in the past 30 days; 2) any binge drinking in the past week; 3) number of binge-drinking days in the past week; and 4) number of drinking days in the past week. The study also measured changes in alcohol use with two alcohol biomarker measures: ethyl glucuronide in urine samples and phosphatidylethanol (PEth) in dried blood spot samples. RESULTS: Ninety-three percent completed the trial, with 85% of weekly follow-up visits completed. In intention-to-treat analyses, naltrexone was associated with a significantly reduced reported number of binge-drinking days (incidence rate ratio [IRR]=0.74, 95% CI=0.56, 0.98; number needed to treat [NNT]=2), weeks with any binge drinking (IRR=0.83, 95% CI=0.72, 0.96; NNT=7.4), number of drinks per month (IRR=0.69, 95% CI=0.52, 0.91; NNT=5.7 for 10 drinks), and alcohol craving scores (coefficient=-9.25, 95% CI=-17.20, -1.31). In as-treated analyses among those who took their medication on average at least 2.5 days per week (the median frequency in the study), naltrexone reduced any binge drinking (IRR=0.84, 95% CI=0.71, 0.99), number of binge-drinking days (IRR=0.67, 95% CI=0.47, 0.96), and PEth concentrations (coefficient=-55.47, 95% CI=-110.75, -0.20). At 6 months posttreatment, naltrexone had sustained effects in number of drinks per month (IRR=0.69, 95% CI=0.50, 0.97), number of binge-drinking days (IRR=0.67, 95% CI=0.47, 0.95), and any binge drinking in the past week (IRR=0.79, 95% CI=0.63, 0.99). CONCLUSIONS: Targeted naltrexone significantly reduced drinking outcomes among SGM with mild to moderate alcohol use disorder during treatment, with sustained effects at 6 months posttreatment. Naltrexone may be an important pharmacotherapy to address binge drinking in populations with mild to moderate alcohol use disorder.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Santos GM, Ikeda J, Coffin P, et al. Targeted Oral Naltrexone for Mild to Moderate Alcohol Use Disorder Among Sexual and Gender Minority Men: A Randomized Trial. Am J Psychiatry. 2022. PMID: 36285404. doi:10.1176/appi.ajp.20220335

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。